- Home
- CCRD vs KLRS Comparison
CCRD vs KLRS Comparison
Compare CCRD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCRD
- KLRS
- Stock Information
- Founded
- CCRD 1973
- KLRS 2019
- Country
- CCRD United States
- KLRS United States
- Employees
- CCRD N/A
- KLRS N/A
- Industry
- CCRD
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCRD
- KLRS Health Care
- Exchange
- CCRD Nasdaq
- KLRS Nasdaq
- Market Cap
- CCRD 157.9M
- KLRS 129.0M
- IPO Year
- CCRD N/A
- KLRS N/A
- Fundamental
- Price
- CCRD $26.31
- KLRS $2.69
- Analyst Decision
- CCRD Hold
- KLRS Buy
- Analyst Count
- CCRD 1
- KLRS 1
- Target Price
- CCRD $21.00
- KLRS N/A
- AVG Volume (30 Days)
- CCRD 54.1K
- KLRS 55.8K
- Earning Date
- CCRD 08-04-2025
- KLRS 08-15-2025
- Dividend Yield
- CCRD N/A
- KLRS N/A
- EPS Growth
- CCRD 187.14
- KLRS N/A
- EPS
- CCRD 0.86
- KLRS N/A
- Revenue
- CCRD $61,011,000.00
- KLRS N/A
- Revenue This Year
- CCRD $17.35
- KLRS N/A
- Revenue Next Year
- CCRD N/A
- KLRS N/A
- P/E Ratio
- CCRD $30.61
- KLRS N/A
- Revenue Growth
- CCRD 12.31
- KLRS N/A
- 52 Week Low
- CCRD $11.57
- KLRS $2.28
- 52 Week High
- CCRD $31.99
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CCRD 41.61
- KLRS N/A
- Support Level
- CCRD $25.65
- KLRS N/A
- Resistance Level
- CCRD $29.40
- KLRS N/A
- Average True Range (ATR)
- CCRD 1.32
- KLRS 0.00
- MACD
- CCRD -0.31
- KLRS 0.00
- Stochastic Oscillator
- CCRD 17.60
- KLRS 0.00
About CCRD CoreCard Corporation
CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.